Rtw Investments Adds $55M in Candel Therapeutics, Inc. ($CADL)
RTW Investments takes a new position in CADL, acquiring over 6.4 million shares.
Key Points
- RTW Investments acquired 6,422,018 shares of CADL, valued at approximately $54.97 million, as reported in its latest 13F filing.
- Shares of CADL traded around $8.56, with recent insider purchases including significant buys by key executives.
- Analysts such as Citigroup and Canaccord Genuity maintain a 'buy' rating on CADL, with price targets as high as $26.
RTW Investments has taken a new position in CADL, acquiring 6,422,018 shares worth around $54.97 million. This move was disclosed in the firm's latest 13F filing, which reflects holdings as of the most recent reporting period.
What Changed in RTW Investments' CADL Position
RTW Investments' latest filing reveals the fund's new acquisition of 6.42 million shares in CADL, marking a substantial new position for the firm. The shares are valued at approximately $54.97 million, with no prior holdings reported.
Other Institutional Activity in CADL
Several other institutional investors have also adjusted their positions in CADL. FMR LLC increased its holdings by 2,752,718 shares, bringing its total to 10,987,017 shares valued at about $53.84 million. Acorn Capital Advisors, LLC added 917,431 shares, ending with 3,497,948 shares worth around $17.21 million. Meanwhile, BlackRock, Inc. grew its stake by 247,353 shares, totaling 3,109,042 shares valued at approximately $15.23 million. Saturn V Capital Management LP and Portolan Capital Management, LLC both made significant additions, with Saturn V acquiring 2,896,588 shares and Portolan adding 1,198,958 shares.
CADL Stock Snapshot
Shares of CADL recently traded around $8.56. The stock has seen varied analyst activity, with some firms maintaining a positive outlook. Despite recent market fluctuations, CADL remains an area of interest for institutional investors.
Insider Buying and Selling at Candel Therapeutics, Inc.
Insider activity at CADL includes several notable purchases. On March 31, 2026, Paul Manning purchased 4,618 shares at an average price of $4.11. Joseph Papa and Nicoletta Loggia also made smaller buys on the same date. Earlier, on February 23, 2026, Manning acquired a significant 550,458 shares at $5.45 each. Additionally, on January 26, 2026, Chief Medical Officer William Garrett Nichols and CFO Charles Schoch purchased 136,500 and 232,000 shares, respectively.
Analysts Set New Price Targets
Analyst activity for CADL has been active. On March 18, 2026, Citigroup maintained its 'buy' rating with a $26 price target. Canaccord Genuity also maintained a 'buy' rating with a $25 target on March 13, 2026. The consensus among analysts remains positive, with a mean price target reflecting optimism about CADL's future.
About CADL
CADL operates in the [sector/industry] and is involved in [brief description of what the company does]. Headquartered in [location], the company is led by CEO [CEO's name] and employs [number of employees] people.
Bottom Line
RTW Investments' new stake in CADL is a notable development, reflecting potential confidence in the company's prospects. While 13F filings are backward-looking, they provide a window into institutional sentiment. Investors often track these filings to gauge the interest of large funds and their investment strategies.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.